問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

803Cases

2019-08-09 - 2022-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis

  • Condition/Disease

    Secondary Hyperparathyroidism

  • Test Drug

    KHK7580

Participate Sites
10Sites

Terminated10Sites

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀
Taipei Veterans General Hospital

Division of Thoracic Medicine

2013-12-23 - 2021-08-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-03-01 - 2022-08-04

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-10-31 - 2016-09-30

Phase III

A phase 3 prospective, multicenter study to evaluate efficacy and safety of rVWF with or without ADVATE in elective surgical procedures in subjects with severe von Willebrand disease

  • Condition/Disease

    von Willebrand Disease

  • Test Drug

    Recombinant von Willebrand Factor / rVWF (BAX111)

Participate Sites
3Sites

Terminated3Sites

2018-01-01 - 2020-05-01

Phase III

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Pimodivir combined with standard care treatment in adolescents, adults, and elderly hospitalized patients with influenza A

  • Condition/Disease

    Influenza A Infection

  • Test Drug

    Pimodivir

Participate Sites
5Sites

Terminated4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2018-06-01 - 2022-09-30

Phase III

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    ONIVYDE

Participate Sites
5Sites

Recruiting5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-03-31 - 2023-12-30

Phase II

A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    Moderate to Severe Active Systemic Lupus Erythematosus

  • Test Drug

    GDC-0853

Participate Sites
8Sites

Terminated6Sites

2016-08-01 - 2020-12-31

Phase I

A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera® in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy

  • Condition/Disease

    Rheumatoid Arthritis (RA)

  • Test Drug

    JHL1101

Participate Sites
3Sites

Terminated3Sites

1 57 58 59 60 61 81
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB